Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Tangen

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Choosing phase II endpoints and designs: evaluating the possibilitiesMichael LeBlanc, Catherine Tangen
JAMA Oncology|November 26, 2015
Surrogates for Survival or Other End Points in OncologyMichael LeBlanc, Catherine Tangen
Journal of the National Cancer Institute|March 17, 2018
Reduced Risk of Prostate Cancer With 5α-Reductase InhibitorsIan Thompson, Phyllis Goodman, Catherine Tangen
World Journal of Urology|May 21, 2003
The Prostate Cancer Prevention Trial: design, status, and promiseIan M Thompson, Catherine Tangen, Phyllis Goodman
The Journal of Urology|August 21, 2002
Impact of previous local treatment for prostate cancer on subsequent metastatic diseaseIan M Thompson, Catherine Tangen, Joseph Basler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the DetailsMaha Hussain, Catherine Tangen, Celestia Higano, et al.
The Journal of Urology|April 24, 2024
Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention TrialCathee Till, Phyllis J Goodman, Catherine Tangen, et al.
The Prostate|January 1, 2008
Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatmentYoonJu Song, Catherine Tangen, Phyllis Goodman, et al.
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
Nutrients|April 19, 2017
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention TrialFayth L Miles, Phyllis J Goodman, Catherine Tangen, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Choosing phase II endpoints and designs: evaluating the possibilitiesMichael LeBlanc, Catherine Tangen
JAMA Oncology|November 26, 2015
Surrogates for Survival or Other End Points in OncologyMichael LeBlanc, Catherine Tangen
Journal of the National Cancer Institute|March 17, 2018
Reduced Risk of Prostate Cancer With 5α-Reductase InhibitorsIan Thompson, Phyllis Goodman, Catherine Tangen
World Journal of Urology|May 21, 2003
The Prostate Cancer Prevention Trial: design, status, and promiseIan M Thompson, Catherine Tangen, Phyllis Goodman
The Journal of Urology|August 21, 2002
Impact of previous local treatment for prostate cancer on subsequent metastatic diseaseIan M Thompson, Catherine Tangen, Joseph Basler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the DetailsMaha Hussain, Catherine Tangen, Celestia Higano, et al.
The Journal of Urology|April 24, 2024
Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention TrialCathee Till, Phyllis J Goodman, Catherine Tangen, et al.
The Prostate|January 1, 2008
Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatmentYoonJu Song, Catherine Tangen, Phyllis Goodman, et al.
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
Nutrients|April 19, 2017
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention TrialFayth L Miles, Phyllis J Goodman, Catherine Tangen, et al.
Pageof 4